Ovasave, an Abu Dhabi-based femtech startup focused on fertility and hormonal health, has announced the successful closure of its $1.2 million pre-seed funding round. The investment, which comes from a mix of regional and international backers, is aimed at fuelling the company’s expansion across the GCC and further developing its digital health platform.
The round was led by PlusVC, Annex Investments, and New York-based 25 Madison, with additional support from strategic angel investors and family offices based in the UAE and Saudi Arabia.
With the new capital, Ovasave plans to expand operations into Saudi Arabia this summer, grow corporate partnerships, and launch the next phase of its mobile app. The updated app will feature menstrual cycle tracking, symptom monitoring, AI-driven treatment protocols, and easier access to fertility and hormonal care, part of the company’s mission to shift women’s healthcare from reactive to proactive.
“There is a critical need for timely intervention in women’s health, particularly around fertility and hormonal health. This funding marks a crucial step in our mission to disrupt women’s health and expand access to fertility and hormonal care across the region,” said Torkia Mahloul, Co-founder and CEO of Ovasave.
Ovasave is part of Hub71, Abu Dhabi’s global tech ecosystem, and is registered with the Department of Health of Abu Dhabi. The startup aligns closely with the UAE’s broader healthcare reforms and digital health strategy, which aim to enhance preventive care and support women’s health initiatives.
“Abu Dhabi’s focus on innovation, healthcare, and entrepreneurship has created a competitive environment for founders and investors alike. As an Abu Dhabi-based startup supported by Hub71, Ovasave has benefited from a strong regulatory framework, access to capital, and proximity to regional decision-makers.”
“It’s the right environment to build and scale high-impact ventures, and from here, we are expanding into Saudi Arabia and the wider MENA region,” said Majd Abu Zant, Co-founder of Ovasave.
Ovasave’s growth comes amid a wider boom in FemTech across the MENA region. According to a recent report by FemTech Analytics, the regional market is expected to reach $3.8 billion by 2031, growing at a compound annual growth rate of 15 percent from 2021 to 2031.
With strong investor confidence and a clear expansion strategy, Ovasave is positioning itself as a key player in reshaping the women’s health landscape in the Middle East.
